People with treatment-resistant depression can now take Spravato's ketamine-derived nasal spray as a standalone treatment.

The results, which come on the heels of the FDA’s approval of J&J’s esketamine nasal spray Spravato as a monotherapy for ...

School nurses, teachers or other people trained and qualified would be authorized to administer the nasal spray to a student or staff member experiencing symptoms of an opioid overdose.

CIII allows people who have tried at least two oral antidepressants to use the spray on its own – without the need for more ...

The U.S. Food and Drug Administration (FDA) approved the antidepressant nasal spray Spravato as a standalone treatment for depression in adults.

The NDA is supported by data from a clinical trial that compared the absorption and efficacy of the nasal treatment with oral and IV bumetanide in 68 healthy adults.

The Food and Drug Administration (FDA) recently approved the nasal spray Spravato for the treatment of major depression in ...

Revolutionary nasal spray offers hope by potentially delaying Alzheimer's progression through cutting-edge neurological ...

An ear, nose and throat doctor explains why tipping your head back with a nosebleed could make things worse and what you ...

The approval of Spravato for the monotherapy indication in TRD was supported by data from the randomized, double-blind, ...

Researchers delivered a dose of the “love hormone” oxytocin via a nasal spray to participants and found that it decreased ...

YORK, Pa. — Here are the top health headlines for the week of Jan. 19, 2025. A nasal spray derived from ketamine gets federal clearance to help some people treat depression. The Federal Drug ...